Another drug approved for treatment of low libido disorders in women

HSDD is one of the most common sexual dysfunctions in women, HSDD is characterized by decreased libido, and brings about stress, which often affects women's emotional health, intimacy and overall quality of lifeThe causes of HSDD are associated with imbalances in chemical factors in the brain that affect sexual arousal or inhibitionStatistics show that globally, premenopausal women (18-55 years old) have a low incidence of low libido of about 10 per cent (far higher in developing countries), with an estimated 6 million women in the United States alone suffering from low libidoVyleesi is a "first-in-class" innovative agonist of the Melanocortin 4 receptor (MELanocortin 4 receptor, MC4R), a new drug that can be used with an automatic disposable syringe prior to expected sexual activity, which is not required daily use by HSDD patientsFDA approval is based on Vyleesi's performance in a Phase 3 clinical study project called RECONNECTThe study included two randomized double-blind, placebo-controlled Phase 3 clinical trials, which included a total of 1,247 premenopausal patientsThe results showed that both trials reached a common primary endpoint of the trial, with a significantly higher score of 25 percent for women receiving the sex desire index, significantly better than in the placebo group (17%), and Vyleesi reducing anxiety associated with HSDDVyleesi's common side effects are nausea, vomiting, flush, headache, etc., about 40 percent of patients in clinical trials experience nausea, especially during the first injection, and blood pressure rises after the first injection, usually subsidence within 12 hours, the FDA warnedCurrently, only one drug is approved for the treatment of HSDD in premenopausal women, a company called Sprout's Addyi, also known as "female Viagra." Palatin was granted exclusive rights for development and commercialization by Vyleesi North America in January 2017, and Fosun Pharma has Vyleesi's exclusive commercialization rights in the Chinese marketAMAG estimates that Vyleesi could generate $1 billion in sales if it goes public.